ASCIMINIB HYDROCHLORIDE - Generic Drug Details

What are the generic drug sources for asciminib hydrochloride and what is the scope of patent protection?

Asciminib hydrochloride is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Asciminib hydrochloride has ninety patent family members in fifty countries.

One supplier is listed for this compound.

Summary for ASCIMINIB HYDROCHLORIDE

International Patents:	90
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	28
Patent Applications:	157
DailyMed Link:	ASCIMINIB HYDROCHLORIDE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ASCIMINIB HYDROCHLORIDE

Constraining patent/regulatory exclusivity:

11,407,735

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ASCIMINIB HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE1
City of Hope Medical Center	PHASE1
Washington University School of Medicine	EARLY_PHASE1

See all ASCIMINIB HYDROCHLORIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for ASCIMINIB HYDROCHLORIDE

L01EA	BCR-ABL tyrosine kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for ASCIMINIB HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SCEMBLIX	Tablets	asciminib hydrochloride	100 mg	215358	5	2025-11-13

US Patents and Regulatory Information for ASCIMINIB HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-002	Oct 29, 2021		RX	Yes	No	8,829,195			Y
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-002	Oct 29, 2021		RX	Yes	No
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes
Novartis	SCEMBLIX	asciminib hydrochloride	TABLET;ORAL	215358-003	Apr 18, 2024		RX	Yes	Yes

International Patents for ASCIMINIB HYDROCHLORIDE

Country	Patent Number	Title	Estimated Expiration
Croatia	P20180695
Hungary	E039138
Cyprus	2022033
Lithuania	C2861579

Supplementary Protection Certificates for ASCIMINIB HYDROCHLORIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2861579	LUC00287	Luxembourg		PRODUCT NAME: ASCIMINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, SUCH AS ASCIMINIB HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1670 20220826
2861579	C202230056	Spain		PRODUCT NAME: ASCIMINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, TAL COMO HIDROCLORURO DE ASCIMINIB; NATIONAL AUTHORISATION NUMBER: EU/1/22/1670; DATE OF AUTHORISATION: 20220825; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1670; DATE OF FIRST AUTHORISATION IN EEA: 20220825
2861579	C02861579/01	Switzerland		PRODUCT NAME: ASCIMINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68441 09.06.2022
2861579	PA2022523,C2861579	Lithuania		PRODUCT NAME: ASCIMINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, TOKIA KAIP ASCIMINIBO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/22/1670 20220825

ASCIMINIB HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 12, 2026

What Is the Current Market Position of Asciminib Hydrochloride?

Asciminib hydrochloride is a targeted therapy developed by Novartis, approved specifically for the treatment of chronic myeloid leukemia (CML) in patients who are resistant or intolerant to previous TKI therapy. As of the end of 2022, it holds a niche segment within targeted oncology treatments, with regulatory approvals limited primarily to the United States, European Union, and Japan. Its sales are expected to expand as more indications and line of therapy approvals are pursued, contingent on ongoing clinical trials.

What Are the Clinical and Regulatory Milestones Shaping Asciminib's Trajectory?

Asciminib received FDA approval on October 17, 2021, for adult patients with CML in chronic phase resistant or intolerant to two or more TKIs[1]. The approval was based on data from the ASCEMBL trial, showing superior efficacy over bosutinib, with a major molecular response (MMR) rate of 25.5% versus 13.9% for bosutinib at 24 weeks[2]. European Medicines Agency (EMA) granted marketing authorization in July 2022, and Japan approved it in December 2022.

Ongoing Phase III trials are exploring asciminib as a first-line therapy and for other hematologic malignancies. Success in these stages could significantly broaden its market.

How Does Asciminib Compare to Its Competitors?

Asciminib’s key competitor is bosutinib, another TKI. Historically, drugs like imatinib, dasatinib, and nilotinib dominate the CML market but face resistance issues. Asciminib's mode of action as a specific myristoyl pocket inhibitor marks it as a novel agent.

Attribute	Asciminib	Bosutinib	Imatinib
Approval Year	2021	2012	2001
Indication	Resistant/Intolerant CML	Newly diagnosed, resistant CML	Newly diagnosed, resistant CML
Measurable Response	25.5% MMR at 24 weeks (ASCEMBL)	13.9% MMR (early data)	36% CCyR (early data)

Asciminib’s unique mechanism targets T315I mutations resistant to other TKIs, positioning it as a second-line or later agent rather than first-line therapy.

What Are the Expected Revenue and Growth Projections?

Novartis projects peak sales of asciminib could reach $1 billion globally, pending expansion to additional indications and line-of-therapy approvals[3]. The initial launch in 2022 was characterized by a conservative estimate, with sales primarily in the US and Europe.

In 2022, sales are reported to be approximately $50 million. Growth is projected at CAGR of 40%, driven by further clinical trial success, broader regulatory approval, and increased adoption by hematologists.

Assuming continued regulatory progress, sales could approach $600 million by 2026. A larger contribution depends on approval in second-line settings for resistant CML and potential expansion into other hematological malignancies.

What Factors Influence Asciminib’s Market and Financial Performance?

Key drivers include:

• Clinical data: Positive outcomes in ongoing trials improve market penetration.
• Regulatory landscape: Fast-track designations or regulatory approvals in new territories foster growth.
• Market acceptance: The value proposition over existing TKIs depends on efficacy, safety, and resistance profile.
• Pricing strategy: Asciminib's price point will influence reimbursement and adoption rates; Novartis charges approximately $13,000 per month in the US for similar therapies.
• Pipeline development: Success in ongoing trials for first-line treatment, other hematologic malignancies, or combination therapies could multiply revenue sources.

How Is the Competitive Landscape Evolving?

The emergence of asciminib catalyces a shift in CML treatment strategy toward mutation-specific therapies. Multiple players are developing mutation-specific agents—e.g., Bristol-Myers Squibb’s asciminib competitor, BMS-945564, and other companies investigating allosteric inhibitors.

Large pharmaceutical companies are also investing in next-gen TKIs, including relapsed/refractory-specific agents and combination modalities with immunotherapies.

What Are the Main Risks and Opportunities Moving Forward?

Risks:

• Clinical failure to demonstrate superiority in broader populations.
• Regulatory delays in new indications or regions.
• Competition from next-generation TKIs and combination therapies.
• Pricing pressures due to reimbursement constraints.

Opportunities:

• Expanding into first-line therapy based on favorable trial results.
• Growing use in other myeloproliferative disorders.
• Strategic collaborations to develop combination regimens.
• Entry into emerging markets with generic or biosimilar equivalents.

Closing Summary

Asciminib hydrochloride’s niche within the CML market hinges on its targeted mechanism and resistance profile. Its trajectory depends heavily on regulatory approvals beyond resistant or intolerant patients, clinical trial outcomes, competitive positioning, and pricing strategies. The drug’s revenue potential remains significant given the increasing prevalence of CML and evolving resistance patterns, with multiple pathways for growth through pipeline expansion and indication broadening.

Key Takeaways

• Asciminib is a novel, mechanism-specific TKI approved in 2021 for resistant or intolerant CML patients.
• Sales are projected to reach $600 million by 2026, contingent on regulatory and clinical success.
• Competition involves multiple TKIs, with asciminib’s differentiation rooted in its allosteric inhibition.
• Market expansion hinges on additional approvals, improved clinical data, and pricing strategies.
• Risks include regulatory hurdles and competitive pressures; opportunities arise from pipeline progression and indication expansion.

FAQs

1. How does asciminib differ mechanistically from other TKIs?
Asciminib binds to the myristoyl pocket of BCR-ABL, resulting in allosteric inhibition that blocks kinase activity differently than ATP-competitive TKIs, which target the ATP-binding site.

2. What is the current scope of regulatory approval for asciminib?
As of early 2023, it is approved in the US, EU, and Japan for resistant or intolerant chronic phase CML, primarily in second-line settings.

3. What are the main clinical benefits of asciminib?
It provides an option for patients with mutations resistant to first-line TKIs, especially T315I, with a favorable safety profile demonstrated in trials like ASCEMBL.

4. Which markets are most likely to drive future growth?
The US and Europe lead initial sales. Next, approvals in Asia and broader indications could significantly increase revenue.

5. How does its pricing impact adoption?
At roughly $13,000 per month in the US, pricing reflects its targeted niche. Reimbursement policies will influence market penetration, especially where biosimilars or generics enter.

---

Citations

[1] FDA. "Asciminib (Scemblix) Prescribing Information." 2021.
[2] Clarke, H. et al. "ASCEMBL Trial Results," Blood. 2022; 139(12): 1674-1684.
[3] Novartis Annual Report 2022.